NASDAQ: BPMC

Blueprint Medicines Corporation

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

If you purchased Blueprint Medicines securities and would like to join the prospective action, please click “Join This Class Action.”

Retainer Agreement
See Full Details
Join This Class Action
If you purchased Blueprint Medicines securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On August 17, 2022, before trading hours, Blueprint Medicines announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a deterioration in the absolute improvement in the symptom score from 15.6 points in this most recent trial versus 19.7 in Phase 1.

On this news, Blueprint Medicines’ share price fell $7.38 per share, or 10%, to close at $61.17 per share on August 17, 2022, on unusually heavy trading volume.

Follow us on:
Twitter
Company Name: Blueprint Medicines Corporation
Stock Symbol: BPMC
Class Period: N/A
Court: N/A
Share This Class Action
Join This Class Action

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Case Attorneys

Phillip Kim

New York, Philadelphia Metro

275 Madison Avenue
40th Floor
New York, NY 10016

Tel: (212) 686-1060
Privacy Policy | Accessibility
Scroll to Top